FTC Clears Bristol-Myers' $74B Celgene Buy With Drug Sale
The Federal Trade Commission has accepted Bristol-Myers Squibb Co.'s plan to divest one of Celgene Corp.'s most lucrative drugs, giving the pharmaceutical companies the green light to proceed with their $74...To view the full article, register now.
Already a subscriber? Click here to view full article